

**Listing of Claims**

1. (Currently amended) A ~~composition of matter comprising a spray dried solid dispersion, which dispersion consists~~ consisting of a sparingly water-soluble drug and hydroxypropyl methylcellulose acetate succinate (HPMCAS), said drug being molecularly dispersed and amorphous in said dispersion, and having a drug:polymer weight ratio between 1:0.4 and 1:20, and said dispersion is a homogeneous solid solution of said drug in said HPMCAS.

2. - 3. (Canceled)

4. (Currently amended) A ~~composition as defined in~~ The spray dried solid dispersion of claim 1, wherein said drug is amorphous when undispersed.


5. - 22. (Canceled)

23. (Currently amended) A ~~composition as defined in~~ The spray dried solid dispersion of claim 1, wherein said dispersion is in the form of particles less than 100  $\mu\text{m}$  in diameter.

24. - 27. (Canceled)

28. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is a glycogen phosphorylase inhibitor.

29. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

O=C1C[C@H](C[C@@H](C1)C(=O)N[C@@H](Cc2ccccc2)C(=O)Nc3c[nH]c4cc(Cl)ccc34)[C@H](O)[C@H]2C[C@@H](O)[C@H](O)N2

31. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is a 5-lipoxygenase inhibitor.


O=C(N)Nc1ccccc1Oc2ccc(Oc3ccc(F)cc3)cc2

33. (Withdrawn) A composition defined in claims 1 and 15 wherein said drug is a corticotropic releasing hormone (CRH) inhibitor.

CC(C)C(C)C1=CC=C2C(=C1)OC(=C(C)C)OC2=N

Page 3 of 11

35. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

36. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, wherein said drug is an antipsychotic.

37. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, wherein said drug is ziprasidone.

38. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is selected from griseofulvin, nifedipine, and phenytoin.

39. - 48. (Canceled)

49. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, wherein said dispersion comprises spray dried particles that are solidified in less than 2 seconds.

50. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, ~~wherein said particles have~~ in the form of particles having a residual solvent content less than 2 wt%.

51. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, ~~wherein said particles are in the form of spray dried particles from~~ spray-dried from a solution in which the concentration of drug in the solvent is less than 20 g/100 g and in which the total solids content is less than 25 weight%.

52. (Canceled)

53. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, wherein said drug has a dose to aqueous solubility ratio greater than 100.

54. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, wherein said drug is crystalline when undispersed.

55. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, having a drug:polymer weight ratio between 1:0.5 and 1:20.

56. (Currently amended) ~~A composition as defined in~~ The spray dried solid dispersion of claim 1, having a drug:polymer weight ratio between 1:1 and 1:20.

57. (New) The spray dried solid dispersion of claim 1, wherein said drug is selected from the group consisting of glycogen phosphorylase inhibitors, 5-lipoxygenase inhibitors, corticotropic releasing hormone inhibitors, griseofulvin, nifedipine, and phenytoin.

58. (New) The spray dried solid dispersion of claim 1, wherein said spray dried solid dispersion is supersaturated in said drug.